However, Neviani et al. reported that protein phosphatase 2A (PP2A)-activating drugs (PADs) can markedly reduce the survival and self-renewal of CML quiescent HSCs, but not normal quiescent HSCs through Bcr-Abl kinase-independent and PP2A-mediated inhibition of JAK2 and β-catenin (Neviani et al., 2013). This evidence concerns the gene PTPA and chronic myelogenous leukemia, BCR-ABL1 positive.